FDA warning for Hospira's Indian site but Orchid impact unlikely
This article was originally published in Scrip
Executive Summary
Hospira continues to come under fire for good manufacturing practice (GMP) deviations, with the firm now receiving a US warning letter against its manufacturing facility in Irungattukottai in India. The plant was acquired from Orchid Chemicals and Pharmaceuticals in 2009 as part of a $400 million deal involving the Indian firm's generic injectable finished dosage form business.